Pricing Log in Create free account

Kymera Therapeutics, Inc. (KYMR) vs TG Therapeutics, Inc. (TGTX)

Kymera Therapeutics, Inc. and TG Therapeutics, Inc. are both Biotechnology companies. Kymera Therapeutics, Inc. is the larger, with a market value of $10.9B against $8.9B — 1.2× the size. Kymera Therapeutics, Inc. has negative trailing earnings, so its P/E is not meaningful; TG Therapeutics, Inc. trades at 19.1×. Kymera Therapeutics, Inc. grew revenue faster over the last twelve months: 134.8% against 76.1%. TG Therapeutics, Inc. has the higher net margin (55.2% vs 0.00%) and the higher return on invested capital (10.7% vs −39.3%). Across the 18 metrics below, TG Therapeutics, Inc. leads on 13 and Kymera Therapeutics, Inc. on 5.

Valuation

Metric KYMR TGTX Biotechnology median
P/E n/m 19.11 10.26
P/S 119.82 10.30 9.18
P/B 7.79 13.64 2.05
Price to free cash flow n/m 473.79 24.81
EV/EBITDA n/m 62.00 0.65
EV/Sales 110.58 10.54 8.98
Earnings yield (2.88%) 5.23% (34.89%)
Free cash flow yield (2.30%) 0.21% (24.52%)

Profitability

Metric KYMR TGTX Biotechnology median
Gross margin 100.00% 82.37% 65.16%
Operating margin 0.00% 17.05% 0.00%
Net margin 0.00% 55.22% 0.00%
Free cash flow margin 0.00% 2.17% 0.00%
Return on equity (27.29%) 100.28% (50.12%)
Return on assets (24.36%) 37.70% (45.60%)
Return on invested capital (39.30%) 10.69% 0.00%

Growth

Metric KYMR TGTX Biotechnology median
Revenue growth (TTM) 134.84% 76.08% 6.26%
EPS growth (last fiscal year) (23.83%) 1,746.67% 29.88%
Revenue growth, 5-year CAGR 2.87% 426.73% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric KYMR TGTX Biotechnology median
Debt to equity 0.00 1.23 0.00
Current ratio 11.13 4.27 4.89
Net debt to EBITDA 2.42 0.86 1.01

Dividend

Metric KYMR TGTX Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric KYMR TGTX Biotechnology median
Market cap 10.94b 8.87b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack